Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
EQS-Adhoc: Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24693/Fresenius.svg.png
EQS-Adhoc: Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
EQS-Adhoc: Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
EQS-News: Fresenius Medical Care AG & Co. KGaA: Helen Giza to take over as Chief Executive Officer of Fresenius Medical Care: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
EQS-News: Fresenius Medical Care AG & Co. KGaA: Helen Giza to take over as Chief Executive Officer of Fresenius Medical Care
EQS-News: Fresenius Medical Care AG & Co. KGaA: Helen Giza to take over as Chief Executive Officer of Fresenius Medical Care
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA: Ms. Helen Giza appointed as new CEO of the Management Board; Dr. Carla Kriwet agreed to resign as CEO and member of the Management Board: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA: Ms. Helen Giza appointed as new CEO of the Management Board; Dr. Carla Kriwet agreed to resign as CEO and member of the Management Board
EQS-Adhoc: Fresenius Medical Care AG & Co. KGaA: Ms. Helen Giza appointed as new CEO of the Management Board; Dr. Carla Kriwet agreed to resign as CEO and member of the Management Board
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24071/375px-Stratec-Biomedical-Logo.svg.png
EQS-News: NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE
EQS-News: NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE
Form 8.3 - The Vanguard Group, Inc.: Sanofi: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23760/234px-Sanofi_2011_logo.svg.png
Form 8.3 - The Vanguard Group, Inc.: Sanofi
Form 8.3 - The Vanguard Group, Inc.: Sanofi
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Amgen Inchttp://commons.wikimedia.org/wiki/File:Amgen.svg: AMGEN INC.
Form 8.3 - The Vanguard Group, Inc.: Amgen Inc
Form 8.3 - The Vanguard Group, Inc.: Amgen Inc
Maple Heights Behavioral Health Hosts Ceremony Celebrating Opening: https://mms.businesswire.com/media/20221130005962/en/1651938/5/MH_ribbon_tying_image.jpg
Maple Heights Behavioral Health Hosts Ceremony Celebrating Opening


Maple Heights Behavioral Health, a new hospital at 3955 W. Washington Center Rd., held a ribbon-tying ceremony Wednesday to mark its opening and celebrate the joint venture between Acadia

EQS-News: PAION AG announces change in Management Board : https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
EQS-News: PAION AG announces change in Management Board
EQS-News: PAION AG announces change in Management Board
EQS-Adhoc: PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
EQS-Adhoc: PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023
EQS-Adhoc: PAION AG: CEO Dr. James Phillips leaves the Company as of 30 November 2022, appointment of Supervisory Board member Gregor Siebert as member and new CEO until 30 November 2023
EQS-News: MorphoSys AG: Financial Calendar 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG: Financial Calendar 2023
EQS-News: MorphoSys AG: Financial Calendar 2023
EQS-News: Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014 and Art. 2 (2) and (3) of the Delegated Regulation (EU) 2016/1052: https://assets2.sharewise.com/attachment/file/24054/375px-Dr%C3%A4ger_Logo.svg.png
EQS-News: Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014 and Art. 2 (2) and (3) of the Delegated Regulation (EU) 2016/1052
EQS-News: Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) and (3) of the Regulation (EU) No 596/2014 and Art. 2 (2) and (3) of the Delegated Regulation (EU) 2016/1052
Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants: https://mms.businesswire.com/media/20221127005124/en/1647007/5/Almirall_HQ_in_Barcelona.jpg
Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants


Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE, (FrAmework for ClInicaL trIal participants’ daTA

Waters Introduces New PFAS Quantitation Workflow Enabled by Enhancements to waters_connect Informatics Platform: https://mms.businesswire.com/media/20221122005226/en/1644645/5/Xevo_TQ_Absolute_ESI_Premier_Angle.jpg
Waters Introduces New PFAS Quantitation Workflow Enabled by Enhancements to waters_connect Informatics Platform


Waters Corporation (NYSE:WAT) today announced a new Per-and Polyfluoroalkyl Substances (PFAS) quantitation workflow enabled by enhancements to its waters_connect™ for quantitation software. Through

STAAR Surgical Opens EVO Experience Center in United States: https://mms.businesswire.com/media/20221117005455/en/1641098/5/PHOTO_4.jpg
STAAR Surgical Opens EVO Experience Center in United States


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced the opening of the first company-operated EVO Experience

EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
CenterWell Senior Primary Care 2023 Expansion Plan Includes New Markets of Indiana, Mississippi and Virginia : https://mms.businesswire.com/media/20221116005276/en/1639003/5/8181.jpg
CenterWell Senior Primary Care 2023 Expansion Plan Includes New Markets of Indiana, Mississippi and Virginia


Fast-growing CenterWell Senior Primary Care will continue expanding in 2023, announcing plans to open in new markets including Indiana, Mississippi and Virginia, as well as opening new centers in

EQS-News: PAION AG enters partnership with Viatris and expands sales activities in Europe: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
EQS-News: PAION AG enters partnership with Viatris and expands sales activities in Europe
EQS-News: PAION AG enters partnership with Viatris and expands sales activities in Europe
EQS-News: PAION AG reports financial results for the first nine months of 2022: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
EQS-News: PAION AG reports financial results for the first nine months of 2022
EQS-News: PAION AG reports financial results for the first nine months of 2022
EQS-Adhoc: PAION AG raises EBITDA forecast for fiscal year 2022: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
EQS-Adhoc: PAION AG raises EBITDA forecast for fiscal year 2022
EQS-Adhoc: PAION AG raises EBITDA forecast for fiscal year 2022
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada: https://mms.businesswire.com/media/20221115005460/en/1637032/5/Canada_office_opening.jpg
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada


Novocure (NASDAQ: NVCR) today announced it has opened a new office in Montreal to expand and support its growing business in Canada. Novocure is a global oncology company working to extend survival

CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results


The seventh bullet under Third Quarter 2022 Highlights and Subsequent Events should read: Received an additional $1.0 million under a bridge loan from the Company’s Vice Chair of the Board of